26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3–6 December 2003: update on preclinical and translational research by Lee, Adrian V et al.
1 cdk = cyclin-dependent kinase; ER = estrogen receptor; PCR = polymerase chain reaction; RT = reverse transcription.
Available online http://breast-cancer-research.com/content/6/2/E10
Introduction
The 26th Annual San Antonio Breast Cancer Symposium
was held in San Antonio, Texas on 3–6 December 2003.
Over the past 26 years this meeting has evolved into the
largest conference in the world devoted solely to breast
cancer research. This year there were more than 700
abstract presentations, from 6000 attendees representing
80 countries. This not only included physicians and scien-
tists who presented the newest information on prevention,
diagnosis, and treatment of breast cancer, but also
included breast cancer patient advocates. In the spirit of
the late William L McGuire, who co-founded this sympo-
sium with Charles A Coltman Jr in 1978, cellular and mol-
ecular biology with translational potential was presented,
and the highlights will now be discussed.
Stem cells
The meeting was opened by a plenary lecture on stem
cells in normal breast development and breast cancer by
Max Wicha (University of Michigan, Ann Arbor, Michigan,
USA). Wicha pointed out that many features of stem cells
are also shared with breast cancer cells, including the
ability to self renew and differentiate, telomerase activity,
resistance to damaging agents, and anchorage-indepen-
dent growth and survival (abstract P1 [1]).
Wicha has developed a new in vitro culture system allowing
the propagation of putative stem cells from normal breast
tissue [2]. In this situation, cells grow in perfect spheroids,
termed mammospheres, and show the two classic features
of stem cells: the ability both to self renew and to differenti-
ate. Microarray analysis of these cells showed expression of
many genes that are similar to those expressed in hemopo-
etic cells, neuronal cells, and embryonic stem cells. Impor-
tantly, when overexpressed in the mammary gland, many of
these genes result in tumorigenesis.
Wicha went on to show that breast cancers contain puta-
tive cancer stem cells that can be selected by specific cell
surface markers such as CD44 and CD24. Blockade of
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Abstract
The San Antonio Breast Cancer Symposium is the largest annual meeting devoted solely to breast
cancer research. The late William L McGuire’s vision for this meeting was to stimulate ‘translational
research’, many years before this term became popular. In this way, the San Antonio Breast Cancer
Symposium represents a forum in which basic and clinical researchers present their research side by
side. Each year sees the continued evolution of our understanding of the basic mechanisms of breast
cancer initiation and progression, and the clinical application of this knowledge. Major topics of
discussion at the symposium this year were the cell cycle, new evolving concepts of estrogen receptor
action, breast cancer stem cells, new predictive and prognostic markers (including microarray studies),
and continued exploration of the mechanisms of drug resistance. This report will summarize preclinical
and translational highlights from the meeting.
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the Notch 4 ligand, which is highly expressed in normal
stem cells, can inhibit tumorigenesis by the putative
cancer stem cells, highlighting a possible novel target for
breast cancer therapy.
The cell cycle
Cell cycle deregulation is an extremely important element
in breast cancer progression, and its deregulation reflects
an attractive target for therapeutic intervention. This area
was given special coverage in a mini-symposium entitled
‘Cell Cycle Regulators — Targets for Therapy?’.
Richard Pestell (Georgetown University, Washington, DC,
USA) gave an overall introduction to the cell cycle, but
stressed that our reductionist models of cyclin action can
be misleading (abstract MS1-1 [1]). To this end, Pestell
showed that cyclin D1 has several novel functions that
seem to be unrelated to its action in the G0/G1 phase of
the cell cycle. In particular, migration and invasion are
reduced in cyclin D1-deficient macrophages [3]. In addi-
tion, cyclin D1 was found to be an inhibitor of the peroxi-
some proliferator-activated receptor gamma, as ligands
that activate this receptor cause increased adiopocyte dif-
ferentiation in cyclin D1-deficient fibroblasts [4].
Khandan Keyomarsi (University of Texas MD Anderson
Cancer Center, Houston, Texas, USA) emphasized that
breast cancer reflects deregulation of cell cycle control
and not simply increased rates of cell growth (abstract
MS1-2 [1]). Keyomarsi showed that cyclin E levels have
prognostic value in breast cancer, with patients having
high levels of cyclin E exhibiting shorter disease-free sur-
vival [5]. Furthermore, immunoblot analysis revealed multi-
ple truncated forms of cyclin E, which Keyomarsi has
shown to be associated with increased cdk2 activity.
Overexpression of these smaller truncation products in
cell lines resulted in enhanced S-phase entry, and over-
expression in the mammary glands of mice caused
mammary tumorigenesis. The small, truncated products
are a result of cleavage of cyclin E by elastase. Interest-
ingly, a natural inhibitor of elastase exists, termed elafin,
and expression of elafin is markedly reduced in breast
cancer cell lines compared with normal cell lines. Key-
omarsi has thus provided an attractive hypothesis whereby
loss of elafin leads to enhanced cleavage of cyclin E by
elastase, forming highly active truncation products.
Sandra Swain (National Cancer Institute, Bethesda, Mary-
land, USA) reviewed the development and clinical use of
cyclin-dependent kinase (cdk) inhibitors. The first
inhibitors (flavopiridol and UCN01) show high potency but
are active against all of the cdks. Flavopiridol showed little
activity in phase I and phase II clinical trials, and it had
unacceptable toxicity when combined with chemotherapy.
UCN01 showed better activity in phase I trials and is now
in phase II trials. Subsequent cdk inhibitors such as
roscovitine and BMS38702 are more selective for certain
cdks, but are less potent. These compounds are currently
in preclinical and clinical development. The minimal clinical
activity of the cdk inhibitors as single agents is similar to
that seen to date with tyrosine kinase inhibitors and angio-
genesis inhibitors. This activity highlights the need to have
a better understanding of the basic mechanisms of signal-
ing in these systems and to define biomarkers to select
patients who are likely to respond to these inhibitors.
Prognostic markers
While studies of single factors have generally failed to
provide new prognostic biomarkers with clinical utility, the
hope is that new technologies evaluating many genes or
their products simultaneously may provide new prognosti-
cators. In this regard, Soon Paik (NSABP, Pittsburgh,
Pennsylvania, USA) presented a multigene PCR assay
that can predict recurrence in node-negative breast
cancer patients (abstract 16 [1]). Paik first identified a
large set of ~250 candidate genes based on previous
microarray data sets and other literature, and then mea-
sured these genes in archival paraffin-embedded tissue
using a multigene RT-PCR method. A subset of genes
were identified that correlated with the likelihood of breast
cancer recurrence, and a recurrence score based on
21 genes (including five reference genes) was developed.
These 21 genes were then measured in estrogen receptor
(ER)-positive node-negative patients (NSABP B-20) and
showed a highly significant ability to predict disease recur-
rence, with the RT-PCR assay being the strongest predic-
tor in multivariate analysis.
This abstract, however, was followed by a presentation by
Francisco Esteva (University of Texas MD Anderson
Cancer Center), who showed that the same multigene RT-
PCR assay was not able to predict recurrence in a set of
ER-positive untreated patients (abstract 17 [1]). The dis-
cordance in these studies may reflect the uniqueness of
Esteva’s study set (which unexpectedly showed that high
nuclear grade was associated with favorable outcome) or
may reflect that the training set represented patients who
were all treated with hormone therapy, thus reflecting the
weight assigned to ER-regulated genes in the 21-gene
set. More studies will be needed to determine the utility of
this prognostic multigene RT-PCR assay.
Other investigators utilized microarray technology to
predict response to therapy. Els Bern (JNI, Rotterdam, The
Netherlands) showed that an 81-gene set that was differ-
entially expressed between tamoxifen-sensitive and tamox-
ifen-resistant tumors could be used to accurately predict
response in approximately 80% of cases (abstract 26 [1]).
In order to characterize response to chemotherapeutic
drugs, Debu Tripathy (University of Texas Southwestern
Medical Center, Dallas, Texas, USA) subjected 15 breast
cancer cell lines with differential sensitivity to cisplatin,3
doxorubicin, paclitaxel, and vinorelbine to microarray analy-
sis (abstract 30 [1]). Response-associated patterns were
identified, but these showed little overlap between the dif-
ferent drugs, indicating that different mechanisms are
involved. Expanding the studies to a larger number of cell
lines might result in the identification of more gene expres-
sion markers in common, at least for drugs with similar
mechanisms of action.
Craig Allred (Baylor College of Medicine, Houston, Texas,
USA) presented microarray analysis of the differences
between ductal carcinoma in situ and invasive breast
cancer. His studies revealed more than 1000 genes that
differed in expression, and these genes allowed near-
perfect diagnostic separation (96–100%) between ductal
carcinoma in situ and invasive breast cancer (abstract 13
[1]). Genes important in this separation were involved in
membrane signal transduction, the extracellular matrix, cell
motility, and cell adhesion.
Chris Jones (Institute of Cancer Research, London, UK)
presented an elegant array study analyzing the differences
between normal luminal epithelial cells and myoepithelial
cells (abstract 20 [1]). The authors identified 72 genes
more highly expressed in the luminal epithelial cells, and
identified 132 genes more highly expressed in the myoep-
ithelial cells. Where antibodies were available, specific
overexpression was confirmed by immunohistochemistry
in breast tumor tissue arrays. Most noteworthy, they identi-
fied some proteins such as galectin-3 and osteonectin
that were strong prognostic indicators.
The ER — still surprises?
As indicated by the title of this mini-symposium, ‘The
Estrogen Receptor — Still Surprises?’, the ER keeps
giving scientists new challenges and puzzles. Novel ER
actions on the membrane, activity that is independent of
its direct DNA binding, and its interaction with the tumor
suppressor gene BRCA1 were discussed.
Ellis Levin (Long Beach Veterans Medical Administration
Center, Long Beach, California, USA) indicated that the
ER, via its c-terminal E domain, can interact with caveolin
and reside in caveolin pits in the plasma membrane. Here
the ER can interact with both growth factor and G-protein
coupled pathways to provide signals termed membrane-
initiated steroid signaling, which may be critical for estro-
gen’s ability to promote survival in such tissues as bone,
the heart, and the brain. In addition, Levin showed that
BRCA1 can inhibit membrane-initiated steroid signaling to
ERK1/2 by increasing the expression of the ERK1/2 phos-
phatase MKP1 (abstract MS3-1 [1]).
Data on how the ER contributes to proliferation without
directly binding to DNA but instead by binding and activat-
ing the transcription factor AP-1 were presented by Peter
Kushner (University of California, San Francisco, Califor-
nia, USA) (abstract MS3-2 [1]). Kushner highlighted a
mutant ER (K206A) that shows hypersensitive ER action
on AP-1 elements, but has unchanged activity on an estro-
gen response element. Overexpression of this mutant ER
in the mammary glands of mice led to hyperplasia and
mammary tumorigenesis, although overexpression of the
wild-type ER also caused mammary tumors, indicating the
potential oncogenic action of the ER.
Why do BRCA1 and BRCA2 mutations cause breast
cancer, ovarian cancer, and prostate cancer instead of
cancers in other organs? Data presented by Eliot Rosen
(Georgetown University) might provide an answer
(abstract MS3-3 [1]). Rosen showed that BRCA1 inter-
acts with and represses transcriptional activity of the ER,
thus inhibiting the cell’s response to estrogen [6]. While
details are yet to be discovered, it seems that direct
binding and recruitment of repressive proteins, as well as
inhibition of the coactivator p300, are involved. Most rele-
vant, however, was the finding that BRCA mutations found
in tumors fail to repress the ER, thus providing an exciting
hypothesis of why mutation carriers are especially suscep-
tible to cancer formation in hormone-responsive organs.
While breast cancer in BRCA1 mutation carriers is often
ER-negative, an inability of BRCA1 to inhibit ER action
may explain why bilateral oophorectomy is able to reduce
breast cancer incidence in these patients.
Drug resistance
Several presentations dealt with the problem of drug resis-
tance in breast cancer. A number of these highlighted the
role of tyrosine kinase receptors, in particular the epider-
mal growth factor receptor family, in mediating resistance
to hormone therapy. Steve Johnston (Royal Marsden Hos-
pital, London, UK) highlighted how growth factor recep-
tors can activate the ER in a ligand-independent manner
and cause antiestrogen resistance (abstract MS3-4 [1]).
Johnston also noted that inhibition of this cross-talk is
being tested in a number of current clinical trials using
inhibitors to either growth factor receptors or their down-
stream signaling components.
In this regard, two preclinical studies showed that combin-
ing an epidermal growth factor receptor inhibitor (gefitinib
[Iressa]; Astrazeneca, London, UK) and/or a HER-2
inhibitor (trastuzumab [Herceptin]; Genentech, San Fran-
cisco, California, USA) with antiestrogen therapy can
enhance the response and delay the resistance in MCF-7
breast cancer cells engineered to overexpress HER-2
(abstracts 22 and 25 [1]). Another presentation, however,
showed that MCF-7 cells that become resistant to tamox-
ifen and Iressa show elevated insulin-like growth factor-I
receptor signaling (abstract 1011 [1]), indicating that there
may be yet another pathway to resistance. This suggests
that targeting of multiple receptors may be necessary.
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Conclusion
The 26th San Antonio meeting continued to reflect the
breadth of translational research in breast cancer.
Advances in the understanding of the fundamental basics
of breast cancer initiation and progression are providing
unique opportunities for breast cancer therapeutic inter-
vention. Mini-symposiums such as the one devoted to the
ER, however, show that continued basic and translational
research is needed to fully appreciate the mechanisms of
action of targeted therapies, and hopefully to combat drug
resistance.
Competing interests
None declared.
References
1. Proceedings of the 26th Annual Breast Cancer Symposium.
Breast Cancer Res Treat 2003, 82(Suppl 1):S1-S184.
2. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawa-
mura MJ, Wicha MS: In vitro propagation and transcriptional
profiling of human mammary stem/progenitor cells. Genes
Dev 2003, 17:1253-1270.
3. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, Cammer
M, Chan A, Symons M, Stanley ER, Pestell RG: Cyclin d1
governs adhesion and motility of macrophages. Mol Biol Cell
2003, 14:2005-2015.
4. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese
C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M,
Scherer PE, Jones JG, Whitney KD, Donehower LA, Harris EL,
Rohan T, Johns DC, Pestell RG: Cyclin D1 repression of peroxi-
some proliferator-activated receptor gamma expression and
transactivation. Mol Cell Biol 2003, 23:6159-6173.
5. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Horto-
bagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M,
Herliczek TW, Bascus SS: Cyclin E and survival in patients with
breast cancer. N Engl J Med 2002, 347:1566-1575.
6. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M,
Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM: Role
of direct interaction in BRCA1 inhibition of estrogen receptor
activity. Oncogene 2001, 20:77-87.
Correspondence
Adrian V Lee, Breast Center, Baylor College of Medicine and the
Methodist Hospital, Houston, TX 77030, USA. Tel: +1 713 798 1624;
fax: +1 713 798 1642; e-mail: avlee@breastcenter.tmc.edu
Breast Cancer Research    Vol 6 No 2 Lee et al.